$5.64
9.32% yesterday
Nasdaq, Nov 15, 10:08 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Voyager Therapeutics, Inc. Classifications & Recommendation:

Buy
90%
Hold
10%

Voyager Therapeutics, Inc. Price Target

Target Price $17.22
Price $5.64
Potential
Number of Estimates 9
9 Analysts have issued a price target Voyager Therapeutics, Inc. 2025 . The average Voyager Therapeutics, Inc. target price is $17.22. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend Voyager Therapeutics, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Voyager Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 250.01 86.21
511.12% 65.52%
EBITDA Margin 50.58% -77.60%
146.35% 253.41%
Net Margin 64.79% -63.33%
140.16% 197.75%

9 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2024 . The average Voyager Therapeutics, Inc. sales estimate is

$86.2m
Unlock
. This is
47.36% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$98.5m 39.86%
Unlock
, the lowest is
$57.1m 65.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $250m 511.12%
2024
$86.2m 65.52%
Unlock
2025
$60.0m 30.36%
Unlock
2026
$77.5m 29.17%
Unlock
2027
$82.5m 6.34%
Unlock
2028
$130m 57.08%
Unlock

3 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2024. The average Voyager Therapeutics, Inc. EBITDA estimate is

$-66.9m
Unlock
. This is
573.46% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-60.5m 528.17%
Unlock
, the lowest is
$-74.7m 628.66%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $126m 383.23%
2024
$-66.9m 152.90%
Unlock
2025
$-121m 80.22%
Unlock
2026
$-120m 0.29%
Unlock
2027
$-118m 1.85%
Unlock
2028
$-145m 23.09%
Unlock

EBITDA Margin

2023 50.58% 146.35%
2024
-77.60% 253.41%
Unlock
2025
-200.82% 158.79%
Unlock
2026
-155.03% 22.80%
Unlock
2027
-143.10% 7.70%
Unlock
2028
-112.14% 21.64%
Unlock

9 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Voyager Therapeutics, Inc. net profit estimate is

$-54.6m
Unlock
. This is
239.04% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-36.0m 191.68%
Unlock
, the lowest is
$-86.2m 319.44%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $162m 345.45%
2024
$-54.6m 133.71%
Unlock
2025
$-95.9m 75.70%
Unlock
2026
$-82.8m 13.74%
Unlock
2027
$-83.7m 1.17%
Unlock
2028
$-43.2m 48.42%
Unlock

Net Margin

2023 64.79% 140.16%
2024
-63.33% 197.75%
Unlock
2025
-159.78% 152.30%
Unlock
2026
-106.71% 33.21%
Unlock
2027
-101.52% 4.86%
Unlock
2028
-33.33% 67.17%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 2.97 -1.00
345.45% 133.67%
P/E negative
EV/Sales 0.09

9 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.00
Unlock
. This is
238.89% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.66 191.67%
Unlock
, the lowest is
$-1.58 319.44%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $2.97 345.45%
2024
$-1.00 133.67%
Unlock
2025
$-1.76 76.00%
Unlock
2026
$-1.52 13.64%
Unlock
2027
$-1.54 1.32%
Unlock
2028
$-0.79 48.70%
Unlock

P/E ratio

Current 7.83 51.45%
2024
-5.63 171.90%
Unlock
2025
-3.21 42.98%
Unlock
2026
-3.72 15.89%
Unlock
2027
-3.67 1.34%
Unlock
2028
-7.12 94.01%
Unlock

Based on analysts' sales estimates for 2024, the Voyager Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.05 83.33%
2024
0.09 87.40%
Unlock
2025
0.13 43.65%
Unlock
2026
0.10 22.59%
Unlock
2027
0.10 5.95%
Unlock
2028
0.06 36.33%
Unlock

P/S ratio

Current 1.88 6.66%
2024
3.57 89.98%
Unlock
2025
5.13 43.59%
Unlock
2026
3.97 22.58%
Unlock
2027
3.74 5.96%
Unlock
2028
2.38 36.34%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today